THU636 Prevalence Of Metabolic Syndrome In A Sample Of Hispanic Patients With Polycystic Ovary Syndrome

Abstract

Abstract Disclosure: I.C. Arroyo: None. L. Gonzalez-Rodriguez: None. B. Diaz Rios: None. Y. Rivera-Rodriguez: None. A. Garcia-Irizarry: None. H. Cabrera-Martinez: None. L. Gonzalez-sepulveda: None. C. Perez-Cardona: None. J. Romaguera: None. R. Azziz, MD, MBA, MPH: Advisory Board Member; Self; Arora Forge. Consulting Fee; Self; Rani Therapeutics, Spruce Biosciences, Fortress Biotech, Core Access Surgical Technologies. Grant Recipient; Self; Ferring Pharmaceuticals. Stock Owner; Self; Martin Imaging. PURPOSE: Polycystic ovary syndrome (PCOS) is an endocrinopathy affecting women of reproductive age. It confers an increased risk of comorbidities such as metabolic syndrome (MetS), cardiovascular (CV) disease, diabetes mellitus, and cancer. There is limited information about how this association impacts Hispanic women, a high-risk group for cardiometabolic disease. This study aimed to evaluate the association between PCOS and MetS in a sample of Hispanic patients. METHODS: This is a cross-sectional study of female patients between 21-45 years of age who underwent evaluation for PCOS and MetS. Patients underwent clinical, laboratory, and imaging studies. PCOS was diagnosed using the Rotterdam criteria and MetS was diagnosed using ATP III criteria. Prevalence of MetS and associated variables were compared between groups. RESULTS: Seventy-eight patients were included in this study (63 patients with PCOS+ and 15 patients with PCOS-). Mean age was 31 ± 6 years. PCOS+ patients were younger. MetS were observed in 52.4% of patients PCOS+ vs 40% of patients PCOS- (p>0.05). No significant differences were found in BMI, waist circumference, blood pressures, triglycerides, HDL, fasting glucose levels, insulin levels, and A1c among groups (p>0.05). A higher prevalence of elevated hs-CRP was observed in patients with PCOS+ (60.3%) vs PCOS- (42.9%). CONCLUSION: Our study found a prevalence of 52.4% of MetS in a sample of patients with PCOS+. Previous studies have shown a 41% prevalence of MetS among Puerto Rican women and 44% prevalence in women with PCOS. PCOS is associated with an increased risk of CV disease, cancer, and diabetes, the leading causes of death in PR. Strategies to decrease this prevalence and avoid its complications in our population are imperative. Presentation: Thursday, June 15, 2023